ArticleFrontiers in endocrinology2021
Hyperprolactinemia and Hypopituitarism in Acromegaly and Effect of Pituitary Surgery: Long-Term Follow-up on 529 Patients.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The effect of endoscopic transsphenoidal somatotroph tumors resection on pituitary hormones: systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.Pituitary · 2026Article
- Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study.Pituitary · 2026Article
- Brain Tumors, AI and Psychiatry: Predicting Tumor-Associated Psychiatric Syndromes with Machine Learning and Biomarkers.International journal of molecular sciences · 2025Review
- Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries.Reviews in endocrine & metabolic disorders · 2025Review
- Clinical characteristics and pathological features of growth hormone-secreting pituitary adenoma combined with hyperprolactinemia.Journal of neuro-oncology · 2025Article
- Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas.Endocrine connections · 2025Article
- Predictors of growth hormone level on postoperative day one in patients with acromegaly.Endocrine · 2025Article
- Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly.Frontiers in endocrinology · 2025Article
- Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.Pituitary · 2024Observational
- Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry.Reproductive biology and endocrinology : RB&E · 2024Article
- Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.Qatar medical journal · 2024Article
- Article
- [Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma].Problemy endokrinologii · 2023Observational
- Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.International journal of molecular sciences · 2023Review
- Preoperative and postoperative blood testosterone levels in patients with acromegaly: a prospective study.Frontiers in endocrinology · 2023Article
- Approach of Acromegaly during Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Studies on hyperprolactinemia and hypopituitarism in acromegaly are limited. We aimed to analyze the preoperative status, postoperative alterations, and correlated factors of hyperprolactinemia and hypopituitarism in acromegaly patients. Methods: This is a single-center cohort study with long-term follow-up. We prospectively enrolled 529 acromegaly patients. Hyperprolactinemia and hypopituitarism were evaluated by testing hypothalamus-pituitary-end organ (HPEO) axes hormones before and after surgery. Results: Hyperprolactinemia (39.1%) and hypopituitarism (34.8%) were common in acromegaly. The incidences of axis-specific hypopituitarism varied (hypogonadism, 29.7%; hypothyroidism, 5.9%; adrenal insufficiency, 5.1%), and multiple HPEO axes dysfunction was diagnosed in 5.3% of patients. Patients with preoperative hyperprolactinemia [hazard ratio (HR)=1.39 (1.08-1.79); Conclusion: Hyperprolactinemia and hypopituitarism are common among acromegaly patients and predict worse surgical outcomes. After surgery, improvement and worsening of HPEO axes function co-exist. Correlated factors are identified for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.